[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020012475A - Metodo para tratar el trastorno depresivo mayor. - Google Patents

Metodo para tratar el trastorno depresivo mayor.

Info

Publication number
MX2020012475A
MX2020012475A MX2020012475A MX2020012475A MX2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A
Authority
MX
Mexico
Prior art keywords
depressive disorder
major depressive
treating major
treating
disorder
Prior art date
Application number
MX2020012475A
Other languages
English (en)
Inventor
Elena Kagan
Petra Luise Goelzer
Original Assignee
Clexio Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Biosciences Ltd filed Critical Clexio Biosciences Ltd
Publication of MX2020012475A publication Critical patent/MX2020012475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para la administración segura y eficaz de esketamina.
MX2020012475A 2018-06-27 2019-06-27 Metodo para tratar el trastorno depresivo mayor. MX2020012475A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690419P 2018-06-27 2018-06-27
US201862698323P 2018-07-16 2018-07-16
US201862741564P 2018-10-05 2018-10-05
US201862769264P 2018-11-19 2018-11-19
PCT/IB2019/055453 WO2020003195A1 (en) 2018-06-27 2019-06-27 Method of treating major depressive disorder

Publications (1)

Publication Number Publication Date
MX2020012475A true MX2020012475A (es) 2021-04-28

Family

ID=67909427

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012475A MX2020012475A (es) 2018-06-27 2019-06-27 Metodo para tratar el trastorno depresivo mayor.

Country Status (11)

Country Link
US (2) US12036189B2 (es)
EP (1) EP3813807A1 (es)
JP (2) JP2021529732A (es)
KR (1) KR20210028159A (es)
CN (1) CN112188889A (es)
AU (1) AU2019293515B2 (es)
BR (1) BR112020023882A2 (es)
CA (1) CA3103440A1 (es)
IL (1) IL278759B1 (es)
MX (1) MX2020012475A (es)
WO (1) WO2020003195A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
CA2491572C (en) 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8785500B2 (en) 2006-03-22 2014-07-22 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
MX336789B (es) 2007-08-13 2016-02-02 Inspirion Delivery Technologies Llc Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion.
CN102762207A (zh) 2008-05-09 2012-10-31 爱莫里大学 用于治疗神经精神疾患的nmda受体拮抗剂
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20130236573A1 (en) 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
EP3035918B1 (en) 2013-08-26 2021-06-30 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EP3062778A4 (en) 2013-10-31 2017-07-19 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3287124B1 (en) 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine
CA2961208A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
DK3215147T3 (da) 2014-11-04 2024-04-02 Acadia Pharm Inc Neurodæmpende norketamin-forbindelser og fremgangsmåder
EP3229788A4 (en) 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2018079693A1 (ja) 2016-10-27 2018-05-03 国立大学法人 千葉大学 （ｓ）－ノルケタミンおよびその塩の医薬品としての応用
CA3045148A1 (en) 2016-11-30 2018-06-07 Philip E. Wolfson Ketamine for the treatment of menstrually related symptoms
US11723883B2 (en) 2017-06-23 2023-08-15 Ketabon Gmbh Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
JP2021506924A (ja) 2017-12-22 2021-02-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022543518A (ja) 2019-08-05 2022-10-13 ザ ケタミン リサーチ ファウンデーション 産後症状及び障害の治療のためのケタミン
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Also Published As

Publication number Publication date
JP2021529732A (ja) 2021-11-04
US12036189B2 (en) 2024-07-16
US20240366530A1 (en) 2024-11-07
IL278759A (en) 2021-01-31
BR112020023882A2 (pt) 2021-02-09
AU2019293515A1 (en) 2020-12-03
CA3103440A1 (en) 2020-01-02
EP3813807A1 (en) 2021-05-05
US20200000748A1 (en) 2020-01-02
JP2024041855A (ja) 2024-03-27
KR20210028159A (ko) 2021-03-11
WO2020003195A1 (en) 2020-01-02
AU2019293515B2 (en) 2024-10-24
IL278759B1 (en) 2024-08-01
CN112188889A (zh) 2021-01-05

Similar Documents

Publication Publication Date Title
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2020012475A (es) Metodo para tratar el trastorno depresivo mayor.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
MX2021003903A (es) Terapia combinada para el melanoma.
IL280845A (en) Asketamine dose adjustment for the treatment of clinical depression
MX2017009246A (es) Farmaco de combinacion.
MX2020006297A (es) Variantes de cd19.
PH12018550186A1 (en) Pharmaceutical combinations for treating cancer
ZA201807438B (en) Methods of treating ocular conditions
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2021006326A (es) Inhibidores de pcna.
AU2018337076A1 (en) Method of treatment
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b